Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

Why It Matters

The findings validate a less‑invasive alternative for high‑risk or younger patients, potentially reshaping reintervention strategies and heart‑team decision‑making worldwide.

Key Takeaways

• ViV 1‑yr mortality 5.3% vs 20.8% surgery.
• Stroke rates lower with transcatheter ViV.
• Hospital stay 4 vs 14 days, less complications.
• Surgery yields better valve gradients, but higher early risk.

Pulse Analysis

Bioprosthetic mitral valves are increasingly used, yet structural degeneration typically emerges after a decade, leaving patients—especially those with rheumatic heart disease—facing repeat interventions. Historically, redo surgery has been the default, but it carries 30‑day mortality rates up to 22% and prolonged recovery. The SURViV trial, conducted across seven Brazilian centers, enrolled a relatively young cohort (average 58 years, 72% female) to directly compare transcatheter valve‑in‑valve (ViV) with conventional redo surgery, providing the first randomized evidence in this space.

The trial’s outcomes were striking: one‑year all‑cause death and disabling stroke fell to 5.3% for ViV versus 20.8% for surgery, driven largely by fewer peri‑operative deaths, strokes, major bleeding, and acute kidney injury. Hospitalization was cut from a median 14 days to just four, underscoring the procedural efficiency of the catheter‑based approach. However, surgical patients retained superior valve hemodynamics, with lower mean gradients and larger effective valve areas at 12 months, suggesting that the durability advantage of surgery may emerge over longer horizons. These nuances reinforce the importance of individualized heart‑team assessments that weigh early safety against potential late‑term performance.

Looking ahead, the durability of transcatheter ViV remains the critical unknown. Ongoing imaging follow‑up will address concerns about leaflet thrombosis and gradient progression, while longer‑term survival data will clarify whether the early mortality benefit persists. If durability proves acceptable, guidelines may shift to favor ViV for older, frail patients or those with small prior prostheses, especially in regions where rheumatic disease drives earlier valve implantation. The trial also highlights the need for broader adoption of multidisciplinary decision pathways to optimize outcomes across diverse patient populations.